Association of BMI and major molecular pathological markers of colorectal cancer in men and women.

Background Observational studies have consistently shown that a high BMI is associated with increased risk of colorectal cancer (CRC). However, the underlying mechanisms linking obesity to CRC remain unclear. Objectives To investigate the associations of BMI and CRC by major molecular pathological subtypes of CRC. Methods This analysis included 2407 cases and 2454 controls from a large German population–based case–control study. Information on recent weight and height as well as other demographic and lifestyle data were obtained by standardized interviews. Multinomial logistic regression was used to estimate ORs and 95% CIs for the associations between BMI and risk of CRC by major molecular pathological features: microsatellite instability (MSI), CpG island methylator phenotype (CIMP), B- Raf proto-oncogene serine/threonine kinase (BRAF) mutation, and Kirsten rat sarcoma viral oncogene homolog gene (KRAS) mutation. Results Among women, a higher BMI was differentially and more strongly associated with risk of MSI CRC (OR per 5 kg/m²: 1.69; 95% CI: 1.34, 2.12; P _{heterogeneity} ≤ 0.001), CIMP-high CRC (OR per 5 kg/m²: 1.57; 95% CI: 1.30, 1.89; P _{heterogeneity} ≤ 0.001), BRAF -mutated CRC (OR per 5 kg/m²: 1.56; 95% CI: 1.22, 1.99; P _{heterogeneity} = 0.04), and KRAS -wildtype CRC (OR per 5 kg/m²: 1.35; 95% CI: 1.17, 1.54; P _{heterogeneity} = 0.01), compared with the risk of CRC in subjects with the molecular feature counterpart. In men, no meaningful differences in CRC risk were observed for the investigated molecular feature pairs. For the association of BMI with MSI CRC, we observed effect modification by sex (P _interaction = 0.04). Also, in women, the risk of CRC with the serrated pathway features was more strongly increased with higher BMI than risk of CRC with the traditional pathway features (OR per 5 kg/m²: 1.73; 95% CI: 1.28, 2.34; P _{heterogeneity} = 0.01). Conclusions In women, the relation between BMI and MSI-high CRC seems to be stronger than that between BMI and microsatellite-stable CRC. However, a validation in an independent cohort is needed. This observational study was registered at the German Clinical Trials Register (http://www.drks.de; study ID: DRKS00011793), an approved primary register in the WHO network. [ABSTRACT FROM AUTHOR]